Clinical Trial Update: GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification [Phase 2]

View source ↗

Summary

Phase 2 trial update for GC1118 in recurrent glioblastoma with high EGFR amplification has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• GC1118 (recombinant human anti-EGFR antibody)

Snippet

Sponsor: Samsung Medical Center | Conditions: Glioblastoma, Adult, EGFR Amplification | Phase 2 | Status: COMPLETED